Alethia BioTherapeutics, Inc.

Patent application filed for bone-related validated targets

Published in Medicine and Law Weekly, January 20th, 2006

Alethia BioTherapeutics, Inc., filed a PCT patent application encompassing the intellectual property surrounding new validated targets that play an important functional role in the differentiation and activation of osteoclasts, the bone-specific cells responsible for bone degradation.

These candidate genes were discovered using Alethia's proprietary STAR technology (Subtractive Transcription-based Amplification of mRNA), a unique, patented discovery platform developed by scientists at Alethia to identify key regulators of biological activity in diseased cells and tissues.

These new targets represent a diverse collection of highly specific regulators...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medicine and Law Weekly

Source: Medicine and Law Weekly (2006-01-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry